Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of AD-214 vs Rabeprazole in Healthy Volunteers
NCT04494243Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma drug concentration-time curve at steady state over a dosing interval at Day 29 and Change of integrated gastric acidity at Day 28. Started Aug 2020; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04494243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494243.